Novogen’s (KZIA) “Buy” Rating Reiterated at BTIG Research

Novogen (NASDAQ:KZIA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a report released on Wednesday,Benzinga reports. They currently have a $34.00 target price on the stock. BTIG Research’s price objective indicates a potential upside of 147.40% from the company’s previous close.

KZIA has been the topic of a number of other reports. Laidlaw initiated coverage on shares of Novogen in a report on Wednesday, April 15th. They set a “buy” rating and a $25.00 target price on the stock. Lake Street Capital began coverage on Novogen in a research note on Thursday, June 11th. They set a “buy” rating and a $32.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.80.

Get Novogen alerts:

Read Our Latest Stock Analysis on Novogen

Novogen Stock Performance

Novogen stock traded up $0.27 during midday trading on Wednesday, reaching $13.74. 66,326 shares of the stock traded hands, compared to its average volume of 211,654. The company has a 50-day simple moving average of $13.21 and a two-hundred day simple moving average of $9.69. Novogen has a 12-month low of $4.86 and a 12-month high of $17.40.

About Novogen

(Get Free Report)

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.

See Also

• Five stocks we like better than Novogen
• Why ASML’s AI Monopoly Is Still Getting Stronger
• Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
• 2 Quantum Stocks That Could Challenge IonQ’s Leadership
• Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger

Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.